These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20850395)

  • 1. Dyslipidemia in renal disease: causes, consequences and treatment.
    Mesquita J; Varela A; Medina JL
    Endocrinol Nutr; 2010 Nov; 57(9):440-8. PubMed ID: 20850395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia in chronic kidney disease.
    Kowalski A; Krikorian A; Lerma EV
    Dis Mon; 2015 Sep; 61(9):396-402. PubMed ID: 26315102
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chronic renal insufficiency and cardiovascular disease].
    Charriere S; Rognant N; Chiche F; Cremer A; Deray G; Priou M
    Ann Cardiol Angeiol (Paris); 2009 Feb; 58(1):40-52. PubMed ID: 18937921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid changes and statins in chronic renal insufficiency.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S226-30. PubMed ID: 17130266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of treatment for dyslipidemia in CKD].
    Ikemori A; Kimura K
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1287-94. PubMed ID: 24288965
    [No Abstract]   [Full Text] [Related]  

  • 9. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
    Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
    Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 11. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia and its management after renal transplantation.
    Andany MA; Kasiske BL
    J Nephrol; 2001; 14 Suppl 4():S81-8. PubMed ID: 11798152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolism in dialysis patients-the story gets more complicated.
    Ponda MP; Barash I
    Semin Dial; 2008; 21(5):390-4. PubMed ID: 18764791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein metabolism and lipid management in chronic kidney disease.
    Kwan BC; Kronenberg F; Beddhu S; Cheung AK
    J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943
    [No Abstract]   [Full Text] [Related]  

  • 18. At which stage of chronic kidney disease should dyslipidemia be treated?
    Krane V; Wanner C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):176-7. PubMed ID: 16932418
    [No Abstract]   [Full Text] [Related]  

  • 19. Statins in patients with chronic kidney disease: new evidence.
    Savino M; Garofalo C; De Paris V; Michini C; Pirro L; Palmisano R; Provenzano M; Minutolo R; Conte G; De Nicola L
    Minerva Urol Nefrol; 2013 Sep; 65(3):217-23. PubMed ID: 23872633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia, inflammation and dialysis outcomes: what we know now.
    Krane V; Drechsler C; Wanner C
    Curr Opin Nephrol Hypertens; 2006 Nov; 15(6):566-70. PubMed ID: 17053468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.